Lite Strategy, Inc. (NasdaqCM: LITS)
Health Care · Biotechnology · US
$1.01
+2.05% today · -80.1% 1Y
Lite Strategy, Inc. (NasdaqCM: LITS) operates in the Biotechnology industry within the Health Care sector. The company is valued at $33.67M and employs 4 people.
Over the last twelve months the share price has lost 80.1%, trading between 0.69 and 5.50.
Tweenvest scores Lite Strategy, Inc. across four factors: quality 36/100. Its strongest factor is quality.
LITS price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $33.67M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -2.21
- Dividend yield
- —
- Beta (5Y)
- 0.03
- 52-week high
- $5.50
- 52-week low
- $0.69
- Avg volume (3M)
- —
- Shares outstanding
- 34.03M
- Employees
- 4
- Next earnings
- —
About Lite Strategy, Inc.
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially changed its designation to Lite Strategy, Inc. in September 2025. The company was established in 2000 and has its principal operations located in San Diego, California.
- ISIN
- US55279B3015
- Founded
- 2000
- Listed since
- Dec 18, 2003
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $261.03 | -1.79% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.19 | -0.24% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.67 | -0.07% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $549.12 | -0.67% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $820.43 | -1.58% |
| argenx SEENXTBR: ARGX | $64.17B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $145.92 | -8.13% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.